Structural insights into the activation and inhibition of CXC chemokine receptor 3
Haizhan Jiao1, Bin Pang2, Aijun Liu1
1Kobilka Institute of Innovative Drug Discovery, School of Medicine, The Chinese University of Hong Kong, Shenzhen, Shenzhen, China.
Insights
Researchers elucidated the structural basis for CXCR3 receptor activation and inhibition. Understanding these mechanisms, involving chemokines and novel agonists/antagonists, offers insights for developing new type 1 immunity drugs.
Area of Science:
- Immunology
- Structural Biology
- Pharmacology
Background:
- Chemokine receptor CXCR3 (CXC chemokine receptor 3) and its ligands (CXCL9-11) are crucial for type 1 immunity, guiding T cell migration.
- Dysregulation of CXCR3 signaling is implicated in various immune-related diseases.
Purpose of the Study:
- To determine the structures of human CXCR3 in complex with various agonists and an antagonist.
- To elucidate the molecular mechanisms underlying CXCR3 activation and inhibition.
Main Methods:
- X-ray crystallography was used to determine the structures of CXCR3 complexes.
- Biochemical assays were employed to characterize the pharmacological properties of modulators.
Main Results:
- Structures revealed distinct binding modes for agonists CXCL11, PS372424, and VUF11222.
- A novel allosteric binding site for antagonist SCH546738 was identified between transmembrane helices 5 and 6.
- SCH546738 appears to stabilize an inactive receptor conformation.
Conclusions:
- The study provides detailed structural insights into CXCR3 activation by different classes of ligands.
- The findings illuminate the allosteric inhibition mechanism of CXCR3.
- This work lays the foundation for structure-based drug design targeting CXCR3 for immune modulation.
Abstract:
The chemotaxis of CD4+ type 1 helper cells and CD8+ cytotoxic lymphocytes, guided by interferon-inducible CXC chemokine 9-11 (CXCL9-11) and CXC chemokine receptor 3 (CXCR3), plays a critical role in type 1 immunity. Here we determined the structures of human CXCR3-DNGi complexes activated by chemokine CXCL11, peptidomimetic agonist PS372424 and biaryl-type agonist VUF11222, and the structure of inactive CXCR3 bound to noncompetitive antagonist SCH546738. Structural analysis revealed that PS372424 shares a similar orthosteric binding pocket to the N terminus of CXCL11, while VUF11222 buries deeper and activates the receptor in a distinct manner. We showed an allosteric binding site between TM5 and TM6, accommodating SCH546738 in the inactive CXCR3. SCH546738 may restrain the receptor at an inactive state by preventing the repacking of TM5 and TM6. By revealing the binding patterns and the pharmacological properties of the four modulators, we present the activation mechanisms of CXCR3 and provide insights for future drug development.
More Related Videos
10:03Rapid and Robust Analysis of Cellular and Molecular Polarization Induced by Chemokine Signaling
Published on: December 12, 2014
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
Related Concept Videos
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The Two-State Receptor Model
The binding affinity of a drug determines its interaction with...
Co-activators and Co-repressors
Calmodulin-dependent Signaling
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
The JAK-STAT Signaling Pathway
Ligand-Gated Ion Channel Receptor: Gating Mechanism
